Upgrade to SI Premium - Free Trial

Stifel Reiterates Hold Rating on Summit Therapeutics plc (SMMT)

February 24, 2025 1:40 PM
Stifel analyst Brad Canino reiterated a Hold rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles